Lexicon Pharmaceuticals Share Up 6.6% as FDA Grants Approval to Heart-Failure Treatment Inpefa
27 May 2023 - 7:25AM
Dow Jones News
By Sabela Ojea
Shares of Lexicon Pharmaceuticals on Friday rose 6.6% to $3.39
in after-hours trading following news the company's heart-failure
treatment Inpefa received U.S. Food and Administration
approval.
The biopharmaceutical company said the approval of Inpefa,
expected to be commercially available in the U.S. by the end of
June, was based on the outcomes of two Phase 3 cardiovascular
studies.
Inpefa, a once-daily oral tablet known generically as
sotagliflozin, targets the risk of cardiovascular death, urgent
heart failure medical visits and hospitalizations in adults with
heart failure of type 2 diabetes mellitus and chronic kidney
disease, among other cardiovascular risk factors.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
May 26, 2023 17:10 ET (21:10 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Apr 2023 to Apr 2024
